Grifols (GRFS) Non Operating Investment Income (2015 - 2016)

Grifols (GRFS) reported Non Operating Investment Income of $3.3 million for Q1 2016, down 59.04% quarter-over-quarter from $8.1 million in Q4 2015.

Grifols (GRFS) Non Operating Investment Income (2015 - 2016) Analysis & Trends

Grifols has reported Non Operating Investment Income for 2 years, with the latest figure at $3.3 million in Q1 2016.

For the quarter ending Q1 2016, Non Operating Investment Income changed N/A year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2016 stood at $3.3 million (changed N/A YoY), and the FY2015 full-year result was $8.1 million, changed N/A from the prior year.
Non Operating Investment Income for Q1 2016 stood at $3.3 million, down from $8.1 million in the prior quarter.
The five-year high for Non Operating Investment Income was $8.1 million in Q4 2015, with the low at $3.3 million in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	-
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	-
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	-
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	-
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	-
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	-
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	-
10	Grifols	6.05 Bn	5.09 Bn	-	-

Download Data